AnaCardio
AnaCardio is a clinical-stage biopharmaceutical company developing medicines intended to improve heart muscle function in people with heart failure.
€62.5MSeries B
ParticipantPB
Pureos Bioventures
Activity from announced rounds
Activity in this selectionxyz-venture-capital-d246227f
- Rounds participated in
- 2
- Confirmed lead rounds
- 1 All roles disclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $100.5M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionNovaGo Therapeutics
NovaGo Therapeutics is a clinical-stage biotech developing anti-Nogo-A antibodies intended to promote nerve regeneration and functional recovery after central nervous system injury.
CHF 24MSeries B
Lead